New Immunotherapy Supplier for High-Risk Neuroblastoma

New Immunotherapy Supplier for High-Risk Neuroblastoma

A New European supplier of Dinutximab Beta has been confirmed, ensuring the ongoing provision of fully-funded, standard of care immunotherapy for high-risk neuroblastoma.

Click here for a full update.

No Comments

Post A Comment